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1. Introduction 
The original dialysate sodium prescription was 126.5 mEq/L (Kolff, 1947). Before volumetric 
controlled ultrafiltration, sodium was removed primarily, slowly and most predictably by 
diffusion. With the development of high flux dialysis membranes, dialysate osmolality 
asserted a faster and more dramatic effect on serum osmolality. Hypotonic dialysate rapidly 
drops serum osmolality that leads to net fluid shift out of the vascular space, causing 
significant intradialytic symptoms (Stewart et al., 1972). Further, the duration of dialysis 
sessions was shortened as clearance of urea was improved, requiring an accelerated rate of 
ultrafiltration. 
To counter symptoms of hypo-osmolarity and rapid ultrafiltration, dialysate sodium 
concentration was increased. In the early 1970s, Stewart demonstrated less cramping with 
sodium of 145 mEq/L than with 132 mEq/L (Stewart et al., 1972). In the early 1980s, 
Locatelli showed improved cardiovascular stability when sodium concentration was raised 
to 148 mEq/L from 142 mEq/L (Locatelli et al., 1982). As the sodium prescription increased, 
concerns about sodium overloading arose. In 1985, Cybulsky demonstrated worsening of 
hypertension in already hypertensive patients (Cybulsky et al., 1985); and Daugirdas 
showed increasing thirst and interdialytic weight gain (IDWG), in both level and modelled 
high sodium techniques (Daugirdas et al., 1985). Nevertheless, intradialytic hemodynamic 
stability remained a valid concern and the data were not always clear. For example, Barré 
showed no worsening of hypertension and pulmonary edema at  [Na+] 145, 150 and 155 
mEq/L (Barré, 1988). The technique of sodium modelling offered a theoretical means to 
attenuate the risk of sodium loading. By the early 1990s, Acchiardo advocated, “[s]odium 
modelling [149mEq/L dropping to 140 mEq/L] should always be used in patients being 
maintained on high flux dialysis” (Acchiardo & Hayden, 1991). This approach was widely 
practiced throughout the 1990s. After more than a decade of high sodium and sodium 
profiling dialysis, trends toward exacerbation of hypertension and interdialytic weight gain 
were becoming evident (Song, 2002). 
Despite a growing body of literature on the effects of dialysis sodium, the sodium 
prescription is frequently overlooked or ineffectually utilized. Further, despite the 
increasing sophistication of dialysis delivery systems, the sodium prescription is often not 
adjusted to suit individual patient needs. First, we will erect a conceptual framework for 
understanding the dialysate sodium prescription. Second, we will review the primary 
literature regarding dialysate sodium and outcomes. Third, we will formulate 
recommendations on prescribing dialysate sodium. Finally, we will explore the technical 
and systems challenges to adjusting the actual sodium delivered to an individual patient.  
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2. Theoretical framework for consideration of dialysate sodium 
2.1 The relationship of sodium to volume 
Traditionally, sodium content of the body and extracellular volume are equivalent concepts. 
Sodium concentration is a function of osmotic regulation while total sodium content is a 
function volume regulation. In renal, hepatic, or cardiac impairment, excess sodium cannot be 
adequately offloaded, leading to extracellular fluid accumulation in the form of peripheral and 
pulmonary edema, and ascites. Dialysis offers a means of volume regulation in the form of 
ultrafiltration. Hydrostatic gradients generated across the dialysis membrane are used to 
remove (relatively) isotonic fluid from the vascular space. Intradialytic weight gain (IDWG) is 
a function of the salt and water intake between dialysis sessions. Increased IDWG is attributed 
to dietary non-compliance; conversely, decreased IDWG reflects excellent dietary compliance 
or can be a harbinger of poor nutritional status as low salt intake can parallel inadequate 
protein-calorie intake (Sarkar et al., 2006). These mutually confounding factors must always be 
recognized when designing or evaluating outcomes research evaluating IDWG. An occult 
source of sodium can offset even the most compliant diet: hypertonic dialysate. While the 
programmed hydrostatic gradient moves sodium (volume) out of the patient in the form of 
ultrafiltrate, osmotic gradients can move sodium in or out of the patient by diffusion.  
2.2 Defining the sodium space 
When dialyzing against hypertonic sodium, patient’s sodium rises – but not so much that 
causes adverse osmotic sequelae. Problems arise by utilizing the osmotic utility of elevated 
interdialytic serum sodium without weighing the volume implications. When using 
profiling techniques, serum sodium concentration only increased from a predialysis average 
of 138.6 +/- 0.2 to 141.0 +/- 0.1 when dialyzing against an average dialysate sodium of 
147mEq/L (Song et al., 2002). This change is an increase in of 2.4mEq/L; multiplying by the 
volume of distribution of sodium in a 70kg male patient results in 33meq of sodium 
transferred by diffusion. Once the set-point serum osmolality is restored by oral fluid intake, 
this represents just a little more than 200cc of normal saline (NS). As an osmotic agent, 
however, sodium’s effects are distributed beyond the extracellular fluid. A change in serum 
sodium reflects a change in total body osmolality, or “total body cation” (Charra & Chazot, 
2003; Gotch et al., 1980). When the extracellular sodium concentration rises, intracellular 
water will diffuse into the extracellular space reaching a new equilibrium: the predominant 
intracellular cation, potassium, would rise similarly to the extracellular sodium. Using the 
data presented by Song et al. (2002), an increase in serum sodium of 2.4mEq/L could be 
multiplied across the total body water; in a 70kg person this would result in a net diffusion 
of 100mEq of sodium, equivalent to 650cc of NS. Based on these calculations, the increase in 
IDWG should be between 0.20kg (ΔNa+ ≈ Δextracellular volume) and 0.65kg (Δsodium ≈ 
Δtotal body cation). The measured increase in IDWG, however, was greater than either 
calculated value. IDWG increased by 1.20kg. It is clear that the “osmolar space” is greater 
than the total body water. The body must be able to store sodium/osmoles outside the 
osmolar pool. 
2.3 Non-Osmotic sodium 
Increasing serum osmolality causes increased thirst leading to rapid re-accumulation of 
volume. As demonstrated above, this cannot account for all the sodium/volume transfer of 
hypertonic dialysate. Hypertonic dialysate causes sodium to accumulate in the extracellular 
www.intechopen.com
 
Sodium and Hemodialysis 
 
49 
matrix in a concentration dependent, non-osmotic fashion. In a now classic experiment, Saul 
Farber, Maxwell Schubert, and Nancy Schuster demonstrated how sodium behaves in 
connective tissue (Farber et al., 1957). Completely ionized chondroitin sulfate can complex 
with “countercations” at a ratio of 1:100. Every mol of chondroitin can associate with 100 
mols of sodium- thereby reducing soluble (osmotically active) sodium. The proportion of 
sodium complexed with chondroitin is positively correlated to the concentration of sodium 
in the surrounding solution. In addition to chondroitin sulfate, hyaluronic acid and other 
mucopolysaccharides can interact with multiple sodium ions (Dunstone, 1959; Schubert, 
1964). Given relative equal binding capacity of chondroitin sulfate for most cations (Na+, K+, 
Mg2+, Ca2+, Sr2+, Ba2+), the relative concentration will determine the quantity of ion bound to 
the polyanion (Woodbury, 1956). Therefore, when the serum sodium concentration is 
increased (such as when dialyzing against a high sodium dialysate), it follows that the 
sodium content of the mucopolysaccharides will also increase. As each ion of sodium 
complexes with a polyanion, it leaves the osmotic pool, leaving a lower serum sodium 
concentration - restoring the dialysate:serum sodium gradient. Sodium will continue to 
diffuse into the patient until the polyanions are saturated while the patient osmolality will 
not rise appreciably. Thus, the net transfer of sodium into the patient will be much more 
than simply the difference between the predialysis and postdialysis serum sodium as 
demonstrated by the calculations in paragraph 2.2. When dialysis is complete, water intake 
will eventually restore serum sodium to the set-point determined by the hypothalamic 
osmostat. The mucopolysaccharide sodium reservoir will release sodium into the osmotic 
pool, stimulating thirst and driving extracellular volume expansion.  
Polyanions are ubiquitously distributed: bone (Woodbury, 1956), cartilage (Dunstone, 1959), 
blood vessels (Tobain et al., 1961), liver, intestine, brain, kidney (Law, 1984), lung and skin 
(Titze et al., 2003). Given this distribution, it should not be surprising that extracellular, 
soluble sodium makes up approximately 75% of total body sodium (Bergstrom, 1955). 
Therefore, 25% of total body sodium is sequestered out of the extracellular osmotic pool. 
The amplitude of the effect of non-osmotic sodium reservoirs should be significant.   
The typical acid/base cycle in hemodialysis patients amplify pathologic sodium binding & 
release of polyanions, especially those of bone. Approximately 25% of total body sodium is 
sequestered in the bone and cartilage (Harrison, 1936). Thirty to forty percent of skeletal 
sodium is exchangeable with circulating sodium every 24hrs (Kaltreider, 1941; Forbes & 
Perley, 1951; Forbes & Lewis, 1956). During acidosis, sodium is freed from the bone, the 
hydrogen ion displacing the sodium ion (Levitt, 1955; Bergstrom, 1955). This model 
approximates the interdialytic period. The inverse process occurs during dialysis; as pH 
rapidly corrects, H+ ions disassociate from bone easily leaving room for sodium – a process 
amplified by high dialysate sodium. After dialysis, pH begins to fall; hydrogen ions 
reaccumulate, displacing bound sodium back into the osmotically active sodium pool, 
driving volume expansion.  
Polyanions are not a static quantity. A high sodium environment leads to increased 
glycosaminoglycans synthesis: the expression mRNA of various enzymes for the synthesis 
of glycosaminoglycans increases 120% to 210% during high sodium intake (Heer, 2009).  
Increased polyanion synthesis leads to an expansion of the non-osmotic sodium pool. 
Further, there is increasing evidence that hypertonic stress and sodium overload stimulate 
mononuclear phagocyte system cells to release vascular endothelial growth factor C (VEGF-
C) promoting lymphangiogenesis (Titze & Machnik, 2010). Thus, hypertonic dialysate may 
stimulate the creation of reservoirs for further sodium storage. 
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3. Review of the primary literature: dialysate sodium and outcomes 
At least fourteen studies can be identified that examine the relationship between variation in 
the dialysate sodium prescription and various clinical measures. Four retrospective, case-
control studies and ten prospective, cohort studies were identified. Three additional studies 
examine variation of dialysate conductivity in a similar manner. 
3.1 Retrospective studies 
As seen in Table 1, we identified four retrospective studies evaluating the relationship 
between dialysate sodium and interdialytic weight gain and blood pressure control. In these 
chart-review approaches, patients were compared in a case-control manner. In two studies, 
58 patients dialyzed against the same sodium bath of 143mEq/L (Keen & Gotch, 2007; Levin 
et al., 2001). Patient’s pre-dialysis serum sodium ‘set point’ was compared to the dialysate 
sodium resulting in a positive or negative “sodium gradient.” Patients with a negative 
gradient had a serum sodium concentration greater than the dialysate sodium 
concentration; these patients had better interdialytic weight gain and improved blood 
pressure control than those with a positive gradient, without any change in intradialytic 
hypotension. Therefore, the lower the dialysate (compared to the patient’s sodium) the 
better the IDWG and BP control.  
In the two audits, patients dialyzing against a relatively lower sodium concentration had 
less IDWG (Davenport 2006, 2008). In the initial study, lower dialysate sodium was 
correlated with an improvement in BP control (defined as decrease in pre-dialysis blood 
pressure or number of antihypertensives prescribed). However, in the larger follow-up 
study, this relationship did not hold. It must be remembered that this retrospective design 
cannot account for the prescribing physicians reasons for the choice of dialysate sodium. It is 
likely that hypotension prone patients would be prescribed a higher sodium bath and less 
antihypertensives.  
 
 
Author 
(year) 
n 
 
Dialysate [Na+] 
(mEq/L) 
Effect of Lower Dialysate [Na+] on 
IDWG BP Control
Intradialytic 
hypotension 
Keen, Gotch 
(2007) 
58 143 c/w patient’s set pointa improved improved no change 
Levin, Keen 
(2001) 
58 143 c/w patient’s set pointa improved improved N/A 
Davenport 
(2006) 
469 136-139, 140, >140 improved improved no change 
Davenport 
(2008) 
2187 136-139, 140, >140 improved no change improved 
Table 1. Four retrospective studies examining the relationship of dialysate sodium 
prescription on interdialytic weight gain (IDWG), Blood Pressure (BP) Control, and 
Intradialytic hypotension. BP control is defined as improved pre-dialysis blood pressure 
measures and/or reduction in number of antihypertensives prescribed. n = number of 
patients in the study. c/w = ‘compared with’. N/A = data not available. a“Set Point” was 
defined as mean monthly predialysis plasma sodium concentration.  
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3.2 Prospective studies 
As seen in Table 2, we identified ten (10) prospective involving 165 patients evaluating the 
relationship between the dialysate sodium prescription and IDWG, BP control, intradialytic 
hypotension and thirst.  
3.2.1 IDWG 
Of the nine (9) prospective studies reporting data on IDWG, eight (8) showed statistically 
significant improvement in IDWG during dialysis on the lower sodium dialysate. The one 
study that did not show any change in IDWG compared the narrowest sodium difference 
(141mEq/L vs. 138 mEq/L), making it the most susceptible to beta error (Thein et al., 2007). 
This 8 month study did show a blunting of the expected seasonal increase in IDWG and BP 
(Argiles, 2004), perhaps due to the lower sodium dialysate used during the four months of 
winter typically associated with higher IDWG.  
3.2.2 Blood pressure control  
Six prospective studies demonstrate improvement in blood pressure control after switching 
patients to lower dialysate sodium. Blood pressure control is defined as reduction in 
predialysis blood pressure measures or reduction in number of prescribed 
antihypertensives. Three studies showed no change in blood pressure control. No study, 
however, showed worsening blood pressure on lower dialysate sodium. It seems certain 
that a modest reduction in dialysate sodium can have beneficial influence on blood pressure 
management.  
3.2.3 Interdialytic hypotension  
Of the five studies reporting interdialytic hypotensive events, two demonstrated more 
frequent hypotension on the lower sodium dialysate. The first found, 9% fewer dialysis 
sessions complicated by hypotension using higher dialysate sodium (Cybulsky et al., 
1985). Of note, the dialysate sodium used in the “low sodium” cohort was 133mEq/L, the 
second lowest in all of the studies reviewed. However, given the yearlong duration of this 
study, the results cannot be dismissed lightly. The other study showing worsening BP 
stability during dialysis had an increased incident rate of approxamately 10% as well 
(Song, 2002). These studies highlight the limitations of reducing sodium indefinitely. 
There is a lower limit on decreasing serum osmolality before fluid shifts into the 
interstitium enough to cause hypotension. Two studies showed no change in intradialytic 
hypotension. One had the narrowest range of dialysate sodium (Thein et al., 2007) while 
the other had nearly the largest (see table 2 and Daugirdas et al., 1985). One study actually 
demonstrated better hemodyanamic stability on lower sodium dialysate highlighting the 
sometimes paradoxical effects of high sodium (de Paula et al., 2004): As hypertonic 
dialysate drives higher IDWG, ultrafiltration must increase in order to maintain steady 
dry weight. If IDWG becomes great enough, removing this excess fluid will put the 
patient at risk for intradialytic hypotension.  
3.2.4 Thirst   
Effect of dialysate sodium on thirst was quite variable. Thirst is probably most dependent 
on subjective patient factors than any other factor.  
www.intechopen.com
 
Progress in Hemodialysis – From Emergent Biotechnology to Clinical Practice 
 
52
Author 
(Year) 
n 
 
t 
(weeks)
Dialysate [Na+] 
(mEq/L) 
Effect of Lower Dialysate [Na+] on 
IDWG BP Control
Intradialytic 
Hypotension 
Thirst 
Cybulsky 
(1985) 
16 52 133, 144 improvedc improvedf worsened no change 
Daugirdas 
(1985) 
7 12 135, 143, 160/133 model improved no change no change improved 
Barré 
(1988) 
5 24 145, 150, 155 improved no change N/A variable 
Krautzig 
(1998) 
8 24-30 135, 140 improvedd improved N/A N/A 
Kooman 
(2000) 
6 6 136, 140 N/A no change N/Ah N/A 
Song 
(2002) 
11 24 138, 140, 147a improved improvedg worsened N/A 
de Paula 
(2004) 
27 6 138, serum [Na+] x 0.95 improved improvedf improved improved 
Oliver 
(2004) 
15 8 132, 137 improvede N/A N/A worsened 
Thein 
(2007) 
52 32 138, 141 no change improved no change N/A 
Sayarlioglu 
(2007) 
18 8 ‘higher'  to 137 or 135b improved improved N/A N/A 
Table 2. Ten prospective studies examining the relationship of dialysate sodium prescription 
on interdialytic weight gain (IDWG), Blood Pressure (BP) Control, Intradialytic 
Hypotension, and Thirst. BP control is defined as improved pre-dialysis blood pressure 
measures and/or reduction in number of antihypertensives prescribed. Estimated dry 
weight was not changed during these studies. n = number of patients in study. N/A = data 
not available. aPatients on Sodium Profiling with [Na+] expressed as Time Averaged 
Concentration (TAC). bPatients placed on 135 if serum was below 137, and on 137 if serum 
was above 137 (not explained what they did if it WAS 137). No record of baseline Na+ Rx 
prior to the change. cImprovement was seen in the normotensive subset.  dHalf of the 
participants had an unquantified improvement. eImprovement seen in patients with 
baseline IDWG greater than 1kg/day. fImprovement was seen in the ‘previously 
hypertensive' subset. g138 & 140 groups were improved when compared to 147 group. 
hThere was a ‘tendency’ toward worsened intradialytic hypotension, data not reported. 
3.3 Conductivity studies 
Electrical conductivity of solutions reflects the concentration of solute in solution. 
Substituting conductivity measurements for concentration measurements allows real-time 
estimations of solute concentrations. Modeling solute clearance,  sodium mass transfer, and 
access recirculation by differences in pre/post dialyzer conductivity represent powerful 
applications of this technology (Polaschegg, 1993; Locatelli et al., 1995; Petitclerc, 1999). In its 
most straightforward application, dialysate conductivity can be used as a surrogate for 
dialysate sodium concentration with one mS/cm conductivity equivalent to 10meq/L 
sodium. Three short, prospective studies involving 36 patients were identified which 
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examined the effect of lowering dialysate conductivity on blood pressure. One study 
showed improved control in blood pressure as conductivity was decreased (Farmer et al. 
2000). Another study found improvement in blood pressure control and IDWG but 
worsening intradialytic hypotension with decreasing dialysate conductivity (Lambie et al., 
2005). The study with the narrowest range of comparison did not show changes in any 
parameters (Selby et al., 2007).  
 
Author 
(Year) 
n 
t 
(weeks)
Approximate 
[Na+] (mEq/L)b 
Effect of Lower Dialysate Conductivity on 
IDWG BP Control
Intradialytic 
Hypotension 
Thirst 
Farmer 
(2000) 
10 4 132.7, 137.7 no change improved N/A N/A 
Lambie 
(2005) 
16 8a 130,132,134,136 improved improved worsened N/A 
Selby 
(2007) 
10 6 132, 134, 136 no change no change no change no change 
Table 3. Three prospective studies showing the effect of lowering dialysate conductivity on 
interdialytic weight gain (IDWG), Blood Pressure (BP) Control, Intradialytic Hypotension, 
and Thirst. Estimated dry weight was not changed during these studies. n = number of 
patients in study. N/A = data not available. aExact duration not reported, but estimated 
from number of stepwise changes in conductivity and duration of dialysis for each step. 
bCalculated from dialysate conductivity. 
4. Recommendations for the dialysate sodium prescription 
4.1 Facility-wide approach 
As demonstrated above, higher dialysate sodium provides questionable and inconsistent 
benefit for intradialytic hemodynamic stability at the cost of proven exacerbation of 
hypertension and interdialytic weight gain. “Lower” dialysate sodium should therefore be 
preferred, however, the exact definition of “lower” concentration is variable between 
studies. In the prospective studies, “lower” was defined from below 132 mEq/L to 
145mEq/L while “higher” was defined from 137 to 155 or higher. Of the 165 patients in 
these studies, we could identify 131 patients where the exact high and low settings could be 
identified. The weighted average for the lower sodium was 137mEq/L and 143mEq/L for 
the higher sodium settings.  
Given the number of potential barriers to crafting an individualized approach the sodium 
prescription for each patient, implementing a facility-wide change to 137mEq/L may be 
safely recommended. Typically, each dialysis unit sets a ‘usual’ dialysate sodium 
concentration based on the decision of the medical director. The ‘standard’ sodium can serve 
as the default with each provider making individualized changes based on individual 
patient’s needs. Therefore, the initial step is encouraging dialysis directors to choose a 
default dialysate sodium concentration at, or close to, 137mEq/L.  
4.2 Individualized approach  
Several questions must be answered when formulating an individualized dialysate sodium. 
Will changing dialysate sodium cause long-term changes in serum osmolality? Are serum 
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and dialysate sodium estimations equivalent concepts? As will be demonstrated below, 
predialysis serum sodium tends to be relatively constant over time, eliminating the need to 
measure the sodium every treatment. Further, conventions in laboratory reporting and the 
Gibbs-Donnan effect influence the direction of diffusive mass transfer between serum and 
dialysate. 
4.2.1 Sodium setpoint 
Pre-dialysis serum sodium remains rather constant over time. The sodium setpoint in dialysis 
patients is the mean monthly pre-dialysis sodium concentration. In 58 patients over 9 to 16 
months, dialyzing against constant dialysate sodium of 143mEq/L, within-subject variability 
of serum sodium was only 0.62 +/- 0.42 mEq/L (Mean +/- 2 Standard Deviations). Further, 
the average serum sodium among the 58 patients was 137.3 +/- 2.5 mEq/L (mean +/- SD). 
Therefore, 98% of this population was dialyzing against relatively hypertonic dialysate even at 
the rather ‘physiological’ sodium of 143meq/L (Keen & Gotch, 2007). 
Over the short term, the sodium set point remains constant even when dialysate sodium is 
manipulated. During a brief evaluation, 27 patients maintained constant pre-dialysis serum 
sodium despite reduction of dialysate sodium to 95% of serum sodium. The average serum 
sodium was 134.0 +/- 1.4 during the first 3 weeks dialyzing against 138 mEq/L and 
remained 134.0 +/- 1.5 (mean +/- SD) after the decrease (de Paula et al., 2004).  
During longer studies it appears that the sodium set point can be influenced slightly by 
changes of dialysate sodium. Over an 18-week period, 11 patients had a small but 
statistically significant increase in pre-dialysis sodium when the time-averaged 
concentration (TAC) of Na+ was raised from 140 to 147 mEq/L (138.1+/-0.1 to 138.6+/-0.2) 
(Song et al., 2002). Similar findings were seen in subgroup analysis of 52 patients over 8 
months. Patients in the upper tertile of pre-dialysis serum sodium at study entry had a small 
but statically significant decrease in pre-dialysis serum sodium from 141 to 140 mEq/L 
(p=0.003) after the dialysate sodium was dropped from 141 to 138 mEq/L (Thein et al, 2007). 
Several other studies show that the sodium set point may be somewhat more mutable; 
however, each significant change seems to be related to sub- or super-physiologic dialysate 
sodium concentrations (Wilkinson et al., 1977; Fischbach et al., 1988; Acchiardo & Hayden, 
1991). When dialyzing across a physiologic range of dialysate sodium, however, the concept 
of a set point remains valid, as variation of predialysis serum sodium is less than 1% (Song 
et al., 2002; de Paula et al., 2004; Keen & Gotch, 2007; Thein et al, 2007).  
4.2.2 Sodium measurements and Gibbs-Donnan considerations 
By convention, ionometric serum sodium measurements are corrected to reflect sodium 
concentration in the total serum volume thereby giving results to historicalresults equivalent 
to historical flame photometry (Burnett et al., 2000). Given that sodium is distributed only in 
the water phase, laboratory measures will underestimate the sodium available for dialytic 
exchange. Actual values should be raised by 7% given usual levels of proteins and lipids. 
The Gibbs-Donnan effect demonstrates, however, that not all this sodium is available for 
dialytic exchange. Negatively charged plasma proteins interact with a portion of ionized 
sodium essentially removing it from the ionic pool. This effect lowers the “plasma diffusible 
sodium by 4-5%” (Santos, 2008), essentially cancelling out the overestimation of the lab 
value (Lindley, 2009). More correctly, the accounting for plasma proteins is unnecessary as 
lab convention and Gibbs-Donnan cancel each other out; however, lipids are uncharged and 
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therefore do not participate in Gibbs-Donnan. Thus diffusible serum sodium is higher than 
expected in proportion to the lipid content of serum. In patients with relatively normal 
lipids, however, this difference is small enough to be ignored. In summary, dialysate 
sodium set to serum sodium can be considered functionally isonatric.  
4.2.3 Final individualized guidelines 
The default sodium prescription should be equal the serum sodium. Dialysate with identical 
sodium concentration to serum keeps sodium diffusion neutral; this approach relies 
exclusively on ultrafiltration for mass transfer of sodium/volume. If attempting to minimize 
variables, an isotonic dialysate is preferred; in this way ultrafiltration is responsible for the 
net sodium transfer while not being silently counteracted by dialysate sodium diffusing into 
the patient. 
Dialysate with higher sodium concentration than the patient’s serum sodium will provide a 
net sodium transfer into the patient. Hypertonic dialysate is only indicated chronically for 
non-hypertensive patients with significant, recurrent intradialytic hypotension or acutely for 
prevention of disequilibrium syndrome.  
Dialysate with lower sodium concentration than the patient’s serum sodium will accept a 
net sodium transfer out of the patient. If attempting to maximize methods for BP control and 
IDWG management, the utilization of hypotonic dialysate is preferred, insofar as is 
tolerated by interdialytic symptoms. 
5. Technical & systems requirements for adjustment of dialysate sodium  
As with any prescription, benefits are never greater than the level of compliance. In the case 
of dialysate sodium, several technical and systems issues must be understood in order to 
modify a dialysate sodium level. Given the many daily problems that dialysis unit staff 
must face, awareness of the prescribed sodium can easily be overlooked. Further, both 
doctors and staff may not be aware of the mechanisms required to change dialysate sodium. 
Depending on each unit’s equipment and dialysate formulation, changing dialysate sodium 
may cause changes in the other electrolytes; this can cause consternation or confusion.  
Staff awareness of the importance and compliance and Medical director interventions: In 
our experience, despite excellent and capable dialysis staff, modifications to the sodium 
prescription can easily be overlooked. In our unit, dialysate is delivered from a central 
system. The sodium concentration “out of the wall” is determined by the concentrate 
formula ordered by the unit – or even determined by a corporate purchasing office. There 
are several points of intervention. First, medical directors, need to be aware of the level of 
sodium in their concentrates. There are several manufactures of dialysate concentrate each 
with its unique formulation. Further, some manufacturers offer a variety of sodium levels 
within their own product lines. One intervention could be for the medical director to select 
the formulation that delivers the desired default sodium – based on our recommendation 
this would be 137mEq/L (see Paragraph 4.1). Changing the base solution is not the only 
method to vary the sodium in a unit and may not be economical or practical. Even if the 
central supply of dialysate does not match the “Facility-Wide” prescription, the staff can 
change to sodium concentration at each individual dialysis machine. Dialysis unit staff 
should be educated regarding the importance and technique of making changes to match 
the prescription. This education should be done even if the central supply of dialysate has 
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the ‘ideal’ sodium level as eventually an “Individualized” approach should be introduced. 
Staff awareness, training and ‘buy in’ are the only way to deliver individualized sodium. 
5.1 Review of dialysate generation 
Modern dialysate contains bicarbonate; it also contains variable amounts of calcium and 
magnesium. If such a solution were stored for any length of time, calcium and magnesium 
would combine with bicarbonate and precipitate out of solution. Dialysate must also be at 
physiologic pH which is, unfortunately, ideal for bacterial growth. In order to avoid these 
untoward consequences, bicarbonate is kept separate from calcium and magnesium in 
separate solutions or powders. The nomenclatures for these concentrates are “Acid” and 
“Bicarbonate”. The Acid typically consists of sodium, chloride, potassium, magnesium, 
calcium, dextrose, acetate, and sometimes citrate. The Bicarbonate concentrate consists of 
sodium bicarbonate with some brands containing some additional sodium chloride. 
Creation of dialysate is requires mixing the Acid and Bicarbonate solutions in exact 
proportions. This is performed in ‘real time’ in the dialysis machine based on the pre-mixed 
concentrates of Acid and Bicarbonate and the software programmed for each concentrate.  
5.2 Concentrate formulations 
All the liquid and dry concentrates in the Fresenius NaturaLyte® - 4000 Series of Acid and 
Bicarbonate will result in a final sodium concentration of 137mEq/L once mixed. Fresenius 
Citrasate® Series results in a base sodium of 137.3 mEq/L once mixed with the NaturaLyte® 
Bicarbonate (Fresenius, 2010). Rockwell Medical produces three series of formulations 
available in dry and liquid. The Rockwell Medical R-Series results in final sodium 
concentrations of 138, 139, 140, 143 mEq/L. The C-Series results in 137mEq/L. The F-Series 
results in 135 or 138 mEq/L (Rockwell Medical, 2009). Minntech’s Centrisol® results in a 
final sodium concentration of 137 mEq/L and their Renasol® results in 139,140,142,or 143 
mEq/L (Minntech, 2010).   
 
Company/ Product Final Na+ (mEq/L) Na+ from Acid (mEq/L) 
Fresenius   
          NaturaLyte® 137 100 
          Citrasate®  137.3 100.3 
Minntech   
          Centrisol®  137 unlisted 
          Renasol®  139,140,142,143 unlisted 
Rockwell Medical   
          R-Series*  138, 139, 140, 143 79, 80, 81, 84 
          C-Series* 137 100 
          F-Series* 135, 138 100, 103 
Table 4. The default sodium concentration of several available dialysate concentrates and 
the sodium contribution from the acid portion (Fresenius, 2010; Minntech, 2010; Rockwell 
Medical 2009). *RenalPure® Liquid Acid with SteriLyte® Liquid Bicarbonate or Dri-Sate® 
Dry Acid with RenalPure® Powder Bicarbonate.  
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5.3 Dialysate proportioning systems 
Given that both the Acid and Bicarbonate concentrates contain significant sodium (sodium 
chloride in Acid and sodium bicarbonate in the Bicarbonate). The sodium can therefore 
varied by adjusting the dilution of the Acid, Bicarbonate or both. The mechanism of this 
variation is determined by the design and software of the dialysis machine. Each 
manufacturer may have slightly different approach. All models of the Fresenius 2008® series 
(2008H, 2008K, 2008K2, 2008T) have an explicit mechanism behind sodium variation:  the 
amount of Acid concentrate is varied to change the sodium concentration to the target value. 
The other electrolytes in the Acid component will vary in proportion to the sodium change, 
while the electrolytes in the Bicarbonate solution will remain unchanged (Fresenius Medical 
Care, 2001, 2009a, 2009b, 2010).  Other manufactures advertise the ability to vary sodium 
across a wide range. The Gambro Artis® System can vary sodium concentration from 130-
160mEq/L - much wider than the Bicarbonate variability (24-38mEq/L). Therefore the 
majority, if not all, of the variation in sodium is produced from variation in the Acid 
concentrate (Gambro, 2008). Similar ranges apply to the Gambro AK96 Advance® and Bio® 
models:  Sodium varies 130-160mEq/L and Bicarbonate 20-40mEq/L (Gambro, 2009). 
B.Braun’s Dialog+® has a conductivity range from 12-17mS/cm, indicating a wide range of 
sodium variation, however, the relative contribution of Acid and Bicarbonate portions are 
not readily accessible (B.Braun Medical Inc., 2009). The capability and mechanism of sodium 
variation for the Baxter TINA® and ARENA® systems are not easily obtainable in an “open 
access” format. However, given the wide use if sodium modeling over the past two decades, 
any modern dialysis machine probably has the capability to generate individualized sodium 
concentrations. 
Systems like the Fresenius 2008® Series, which hold the Bicarbonate constant and vary the 
Acid in order to alter the sodium, will show the greatest variation in the other electrolytes in 
the acid component. As will be demonstrated below, however, these changes are minute 
and clinically irrelevant. If any of the other systems utilize a combination of Acid and 
Bicarbonate variations to alter sodium concentration, the changes in Acid electrolytes will be 
even less effected (the bicarbonate concentration would vary somewhat, however, the 
change would also be minimal). 
5.4 Electrolyte variability during sodium individualization 
The question arises, will there be a change in other electrolyte components during the 
sodium variation?  Clinically these variations are insignificant and should not hinder the use 
of tailored sodium. Dialysis staff needs to be reassured of this, as many of the newer 
generation dialysis machines will display the changes to all electrolytes when one is 
changed. Some staff may see a small change in the potassium and undo the change because 
the potassium level does not match the prescription. Dialysis unit policy and dialysis orders 
should be written to accept small variation in other electrolytes during adjustment of 
sodium. Of note, during sodium profiling, all the acid electrolytes in the same way, resulting 
in wider, yet still clinically insignificant, fluctuations in the other components.  
Here is an example of the nature of electrolyte variation with individualized sodium. A 
clinician determines that a particular patient’s individualized dialysate sodium should be 
133mEq/L. Some adjustment of the dialysis machine is required as none of the available 
base solutions result in this a sodium of 133mEq/L. A Fresenius 2008T®, for example, 
manipulates the final dialysate sodium by varying concentration of the Acid component 
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(Fresenius Medical Care, 2010a). If the available dialysate has a base sodium of 137mEq/L 
and the Acid concentrate contributes 100mEq/L (such as Fresenius NaturaLyte®, Citrasate® 
or Rockwell Medical C-Series), it is possible to predict the changes on the other electrolytes. 
Reducing the final sodium from 137 to 133 mEq/L requires reducing the Acid component 
from 100meq/L to 96mEq/L (a change of 4%). Reducing each Acid component by 4% will 
give the final concentration of that component. Using a standard Acid solution, such as 
Fresenius NaturaLyte® Product Number 08-2201-5, contributes 100mEq/L of sodium,  
 
Electrolyte 
Product Number / 
Acid Concentration 
New Concentration After 
5meq/L Sodium Decrease 
   
 Fresenius, 08-2201-5 
Na+ (mEq/L) 100 95 (5% reduction) 
K+ (mEq/L) 2.0 1.9 
Ca++ (mEq/L) 2.00 1.90 
Mg++ (mEq/L) 1.00 0.95 
Cl-- (mEq/L) 105.0 99.8 
Acetate (mEq/L) 4.0 3.5 
Dextrose (mg/dL) 100 95 
   
 Rockwell Medical, R-205 
Na+ (mEq/L) 79 74 (6.33% reduction) 
K+ (mEq/L) 3 2.8 
Ca++ (mEq/L) 3.5 3.2 
Mg++ (mEq/L) 1.5 1.4 
Cl-- (mEq/L) 86 80.6 
Acetate (mEq/L) 4 3.7 
Dextrose (mg/dL) 200 187 
   
 Rockwell Medical, F-215 
Na+ (mEq/L) 103 98 (4.85% reduction) 
K+ (mEq/L) 1 0.95 
Ca++ (mEq/L) 2.5 2.37 
Mg++ (mEq/L) 1 0.95 
Cl-- (mEq/L) 107.5 102.3 
Acetate (mEq/L) 3 2.85 
Dextrose (mg/dL) 200 190 
Table 5. Change in electrolyte concentrations resulting from an individualized sodium 
prescription. This example shows what happens to the other electrolytes after a 5mEq/L 
reduction in dialysate sodium. The breakdown of the Acid portion of several common 
concentrates is shown in the center column (Rockwell Medical, 2009; Fresenius Medical 
Care, 2010b).  Based on the percent change of Acid sodium, the resulting values for 
potassium, calcium, magnesium, chloride, acetate and dextrose are listed in the left column.  
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2.00mEq/L of potassium and 100mg/dL of dextrose (Fresenius Medical Care, 2010b). 
Diluting this Acid by 4% results in Na+ 96mEq/L, K+ 1.92mEq/L, and dextrose 96mg/dL. 
None of these changes carry a significant clinical effect. The smaller the sodium contribution 
of the Acid, the other electrolytes will show a larger variation. Table 5 shows the final 
electrolyte changes of several standard dialysate solutions when using the proportioning 
system to decrease the base sodium by 5mEq/L.  
6. Conclusions 
Dialysate sodium concentration must be prescribed for each dialysis session. Dialysate 
sodium standards vary from 126.5mEq/L to greater than 155mEq/L through out the history 
of dialysis. While higher concentrations can be used to promote greater hemodynamic 
stability during dialysis, their cost is worsening hypertension and greater interdialytic 
weight gain. Glycosaminoglycans and other polyanions sequester sodium out of the osmotic 
pool and amplify the sodium gain during hypertonic dialysis causing greater effects than 
the traditional ‘sodium space’ model would predict. We reviewed 17 prospective and 
retrospective studies that quantify the effects of dialysate sodium on hypertension, 
interdialytic weight gain and intradialytic hypotension. In order to minimize undesired 
effects of high or low sodium for the most patients, “facility-wide” dialysate sodium setting 
of 137mEq/L should be implemented. An individualized sodium prescription can be 
calculated by setting dialysate sodium equal the patient’s serum sodium. This calculation 
can be done without adjustments since laboratory conventions and the Gibbs-Donnan effect 
essentially negate each other. In order to deliver a facility-wide or individualized sodium 
prescription, changing dialysate concentrates could be undertaken but not necessary: 
modern proportioning systems can adjust the dilution of dialysate Acid or Bicarbonate 
components. Usually the dilution of the Acid is adjusted while Bicarbonate remains 
constant. The other Acid electrolytes will vary by the same percentage as the sodium 
variation: a clinically inconsequential change.  
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